Scholar Rock Holding Corporation's apitegromab shows promise for SMA treatment, aims for 2025 launch. Click for my updated ...

A case report in Japan shows Spinraza helped a boy with SMA type 0 sit without support for a short time at age 2 and stand ...

The global antisense oligonucleotides market is poised for remarkable growth over the next decade, projected to rise from USD 2,913.5 million in 2023 to USD 5,519.6 million by 2033, according to ...

Affordable generic version of SMA drug Risdiplam soon available in India, offering hope to patients and activists.

FDA-approved treatments for spinal muscular atrophy differ in their mechanisms of action, safety profiles, and administration ...

Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease ...

Nusinersen is currently commercialized under the brand name SPINRAZA in over 71 countries at the label-approved dose of 12 mg. “Continued progress to improve upon the remarkable initial ...

Treatment with Spinraza (nusinersen) can help stabilize motor function in adults with spinal muscular atrophy (SMA), according to a new analysis. “This study aligns with previously reported findings ...

But Biogen isn’t resting on the success of Spinraza. In January 2022, the big biotech exercised an option from Ionis for an exclusive global license for another antisense oligonucleotide, BIIB115, ...

While 3 US Food and Drug Administration (FDA)-approved drugs are available for the treatment of spinal muscular atrophy (SMA), managing the disease requires a multidisciplinary team and approach. SMA ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...